#News: Celcuity reports second quarter 2024 financials and provides recent updates: https://lnkd.in/gK-gdjeX A live webcast/conference call at 4:30 p.m. ET today can be accessed using this weblink: https://lnkd.in/dfzgn9dQ #earnings #oncology #biotechnology
Celcuity’s Post
More Relevant Posts
-
Immutep Limited shares positive survival data from INSIGHT-003 in 1L #NSCLC. With a median overall survival of 32.9 months and progression-free survival at 12.7 months, and 24-month survival reaching 81%, these results demonstrate significant improvement compared to historical controls. Read: https://bit.ly/3YFXLFi #biotechnology #NSCLC #oncology
-
-
The pioneers in LAG-3 show significant 2+ year 1st-line survival in non-squamous NSCLC. Eftilagimod alpha + Keytruda-- synergy adding this novel MHC Class II agonist, even patients with low/neg PD-L1 expression.
Immutep Limited shares positive survival data from INSIGHT-003 in 1L #NSCLC. With a median overall survival of 32.9 months and progression-free survival at 12.7 months, and 24-month survival reaching 81%, these results demonstrate significant improvement compared to historical controls. Read: https://bit.ly/3YFXLFi #biotechnology #NSCLC #oncology
-
-
Following the science is a key discipline for success. Listen to our CEO, Aron Knickerbocker, and his advice for the next generation in #biotech, including how this principle has guided him throughout his career: https://bit.ly/3YIbVpB #Oncology #BusinessofBiotech Bioprocess Online
-
Immutep Limited is pleased to share an Investor Update discussing the upcoming TACTI-004 trial & becoming a Phase 3 biotech. The potential for efti combined with KEYTRUDA & chemo is to set a new standard-of-care in #NSCLC Read more here: https://bit.ly/4eRmFb8 #Biotech #Oncology #LCSM #LungCancerAwarenessMonth
-
Are you using the right model to make your immuno-oncology project successful? Discover the key benefits to all our immuno-deficient models by downloading our updated poster today so we can support your preclinical studies. Download poster: https://okt.to/tg72VS #animalmodels #animalresearch #lifesciences #biotech #science #biotechnology #biomedicalresearch #immunooncology #oncology #researchmodels
-
-
ExoProTher eagerly awaits the State-of-the-Art Envision NTA Machine from HYPERION ANALYTICAL We are excited to share that the brand-new, and Israel's first, Nanoparticle Tracking Analysis (NTA) machine of this kind – Envision from Hyperion Analytical LLC, is on the way to ExoProTher’s labs. The Envision will significantly enhance our analytical capabilities and data reliability. Our investment in the HYPERION NTA Envision underscores our commitment to pioneering science and best quality data behind the development of p53 replacement therapy for oncology indications. Watch this space for more updates! #nanoparticletrackinganalysis #innovation #p53replacementtherapy #biotechnology #oncology
-
-
Are you using the right model to make your immuno-oncology project successful? Discover the key benefits to all our immuno-deficient models by downloading our updated poster today so we can support your preclinical studies. Download poster: https://okt.to/df1ANn #animalmodels #animalresearch #lifesciences #biotech #science #biotechnology #biomedicalresearch #immunooncology #oncology #researchmodels
-
-
Diamond Equity Research: Price Target $0.49 IMU: Announces Up to A$46 Million Financing, Achieves First Intratumoural onCARlytics Dosing Milestone, and Opens First Australian Azer-cel Trial Site for Relapsed or Refractory DLBCL Read the full report here: https://lnkd.in/g5czf8VX #IMU #Imugene #Imugene #AzerCel #CancerResearch #DLBCL #CAR_T #ImmunoOncology #Biotech #ClinicalTrials #CancerTreatment #Oncology #MedicalResearch #equityresearch #equityrelease
-
Latest Diamond Equity Research values Imugene at A$0.49/share. Hunter Diamond, CFA, noted, “Imugene continues to advance its clinical pipeline with significant milestones achieved, including the first patient dosed in the azer-cel Phase 1b trial in Australia and the intratumoural combination arm of its onCARlytics trial. These developments position Imugene to further validate its innovative immuno-oncology therapies and broaden their clinical applicability.” With strategic funding secured and multiple catalysts ahead, Imugene is well-positioned to deliver further progress in its immuno-oncology pipeline through 2025. #ASX #Imugene #ImmunoOncology #CancerResearch #biotech
Diamond Equity Research: Price Target $0.49 IMU: Announces Up to A$46 Million Financing, Achieves First Intratumoural onCARlytics Dosing Milestone, and Opens First Australian Azer-cel Trial Site for Relapsed or Refractory DLBCL Read the full report here: https://lnkd.in/g5czf8VX #IMU #Imugene #Imugene #AzerCel #CancerResearch #DLBCL #CAR_T #ImmunoOncology #Biotech #ClinicalTrials #CancerTreatment #Oncology #MedicalResearch #equityresearch #equityrelease
-
MAIA CEO Vlad Vitoc, MD, MBA shares insight on what to look for in an #oncology trial. Watch more below! #Biotech #OncNews
Healthcare consultant
7moHave you had a chance to check out my new book on complementary cancer therapy? It’s a culmination of ten years of volunteering at Stanford, a journey that began during my time at Genentech. Northern California is truly a hub for alternative therapies, and my role was to sift through them, identifying which ones could truly help and which might pose risks to patients. I poured a lot of care and passion into this project and I hope you find it enlightening and entertaining ☺️🖖 https://www.amazon.com/gp/aw/d/B0CR8Q2DBM/ref=tmm_hrd_swatch_0?ie=UTF8&dib_tag=AUTHOR&dib=eyJ2IjoiMSJ9.95LORH50bfIfbI-ImCAgki92SxXyAgHTLxBkHg4nB10mKtHZR5FZMZqzbfNHGdVjhwtvZaCH-7cdQJAjbvYHCK24NHBpSGzapM_X96Wr1aarL5g9Vnk0jrdQV8dkPq_C.7WpxgPyEYQ3UI9Cl1i7FmCHaMuNB7SbTC8QPEzWf56Y&qid=&sr=